RNS Number: 1347N
DeepMatter Group PLC
28 September 2021
DeepMatter collaborates with Dr. Reddy’s for its DigitalGlassware® platform
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), the international digital chemistry data company, has signed a contract with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), based in Hyderabad, India, for its DigitalGlassware® platform.
DeepMatter will provide its DigitalGlassware® platform to Dr Reddy’s process development team who are looking to the development and scale up of chemistry procedures to handover to colleagues.
This collaboration is part of DeepMatter’s ongoing strategy to provide its DigitalGlassware® platform to the major global Contract Research Organisations (CRO’s) where the need for reproducibility is paramount to accelerate the discovery of new drugs.
Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas and has built strong R&D capabilities not just in India, but worldwide, making it a partner of choice in contract research, development, and manufacturing services. As it seeks to constantly build on its digital capabilities, DigitalGlassware® will look to play a key role in this strategy.
DigitalGlassware® comprises a cloud-based software platform allowing scientists to easily bring together digitised synthesis protocols (recipes) and contextualised time-course sensor streams from a range of analytical instrumentation, importantly in real-time.
Mark Warne, CEO of DeepMatter Group, commented:
"We are focused on creating value for the world’s largest CROs with our DigitalGlassware® platform. We are working with them to firmly establish it as the go-to platform for capturing and structuring time-course sensor data in the lab, to enable improved insights for better productivity and discovery.
“Dr Reddy’s are actively interested in the capture of parameters that they can utilise for their process development and modelling activities. We are working with them to see how DigitalGlassware®, with the use of sensor devices, can aid in the capture of these important parameters and facilitate analysis of runs performed at Dr Reddy’s.”
For more information, please contact:
DeepMatter Group plc
Mark Warne, Chief Executive Officer
T: 0141 548 8156
Canaccord Genuity Limited (Nominated Advisor and Broker)
T: 020 7523 8000
Meare ConsultingAdrian Duffield
T: 07990 858548
About DeepMatter Group plc
DeepMatter is building a unique, fully integrated digital chemistry cloud platform of chemical reaction data for scientists, who are working on early-stage chemical discovery & development.
DeepMatter is integrating technology with chemistry to enable scientists, principally in the commercial sector, to easily perform and optimise chemistry. It is building, structuring and analysing chemical reaction databases and using this substantial data for real-time innovation and productivity gains in the chemical industry - particularly pharmaceutical companies engaged in pre-clinical drug discovery & development. This data is also now enabling Artificial Intelligence (AI) driven chemical automation.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.
For more information, log on to: www.drreddys.com